Revista Española de Cardiología (English Edition) Revista Española de Cardiología (English Edition)
Rev Esp Cardiol. 2017;70:799-800 - Vol. 70 Num.10 DOI: 10.1016/j.rec.2017.04.007

The Role and Impact of Gut Microbiota in Cardiovascular Disease

Takeshi Kitai a, W.H. Wilson Tang a,b,c,

a Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, United States
b Department of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States
c Center for Clinical Genomics, Cleveland Clinic, Cleveland, Ohio, United States

Article

The human gut harbors more than 100 trillion microbial cells, which intricately regulate the normal development and function of mucosal barriers. Over the past decade, we have discovered the substantial inter- and intra-individual variation and versatility of the gut microbiome profile and changes in health and various disease states. Although it is clear that the composition of gut microbiota can be significantly altered in patients with cardiometabolic diseases (also known as “dysbiosis”), much of the data remain largely associative in nature. Thus, the path to further understanding the role of the gut microbiome in health and disease remains exceedingly challenging. Recent studies have identified the gut microbiota as playing a critical role in the pathophysiology of cardiovascular disease (CVD) and chronic kidney disease (CKD). Given that the primary role of the kidneys is to remove metabolites and toxic compounds to maintain body homeostasis, impaired renal function can lead to increased levels of such unwanted compounds. These organic compounds with adverse biological activity are often referred to as “uremic toxins,” such as advanced glycation end products and tryptophan-based metabolites (eg, p-cresyl sulfate and indoxyl sulfate).1 Indeed, altered profiles of gut microbiota composition have been associated with increased production of indoxyl sulfate and p-cresyl sulfate, which is directly associated with endothelial dysfunction, inflammation and oxidative stress, and increases in the incidence of CVD and mortality.2 These data support a gut-renal axis hypothesis contributing to the progression of CVD and CKD.

The gut microbiota interacts with the host via the intestinal mucosal surface, and intestinal epithelial barrier function is maintained by a well-balanced gut microbiota through several mechanisms, including restoration of protein tight junction structure, upregulation of mucin genes, and competition with pathogenic bacteria to bind epithelial cells.3 In the setting of impaired cardiac and/or renal function, intestinal wall edema due to systemic congestion and intestinal wall ischemia may reduce intestinal blood flow, which can result in structural disruption of the epithelial mucosal barrier and increased permeability.4 In addition to hemodynamic deterioration, gut dysbiosis is associated with the production of unwanted toxins and the promotion of a leaky intestinal barrier.5 The disruption of intestinal barrier function allows the translocation of endotoxins, microbial components, and microbial metabolites to enter the systemic circulation, which can induce immune responses and lead to systemic inflammation. Circulating bacterial lipopolysaccharide levels increase with CKD stages and have been associated with a higher mortality risk. Furthermore, bacterial DNA is also detected in the blood of patients with both CVD and CKD.6, 7 Plasma inflammatory markers, such as high-sensitive C-reactive protein and interleukin-6 levels, were higher in patients with bacterial DNA in the blood than in those without.8 In a recent study, a corresponding increase in the amount of fecal intestinal bacteria and fungi has been observed with increasing intestinal permeability in patients with heart failure.9

The discovery of trimethylamine N-oxide (TMAO) production and the development and progression of cardiovascular risk adds another dimension to this complex interplay between gut microbiome and its human host, whereby dietary intake (a form of environmental exposure) interfaces with gut microbiota to generate metabolites that may serve as promoters of cardiorenal diseases. Indeed, circulating TMAO levels have consistently been observed to be elevated in patients with CKD as well as in those with atherosclerotic burden, and have been associated with the development and progression of heart failure and CKD.10, 11 We and others have observed that increased dietary-induced TMAO generation in animal models has been associated with myocardial and renal tubulointerstitial fibrosis.11 Microbial taxa belonging to the clostridiaceae and peptostreptococcaceae families are positively associated with blood levels of TMAO in humans.12 Given the high choline-induced gut microbiota-dependent production of trimethylamine (TMA) and TMAO,13 reduced intake of dietary precursors of TMAO is a potential approach to reduce CVD. We have recently reported that 3,3-dimethyl-1-butanol (DMB), which is a structural analog of choline and an inhibitor of TMA formation through inhibition of microbial TMA lyases, inhibited choline diet-enhanced endogenous macrophage foam cell formation and atherosclerotic lesion development without alterations in circulating cholesterol levels.14 DMB was detected in some balsamic vinegars, red wines, and olive oils, which may in part potentially explain the cardiovascular benefits of the Mediterranean diet.

Besides identifying gut microbiota-derived metabolites that can lead to disease progression, various other metabolites may promote cardiovascular benefits. For example, a connection between blood pressure regulation and microbial short chain fatty acids (SCFAs) has also been gathering attention. Hypertension was associated with changes in the microbiota as well as in SCFAs.15 SCFAs were shown to act through both olfactory receptor 78 (Olf78), which increases blood pressure, and G-protein-coupled receptor 41, which lowers blood pressure.16 High-fiber diets, which increase microbial SCFA production, lowered blood pressure.17 Individuals with lower microbial SCFA levels had higher blood pressure.18 In addition, SCFAs also reduced acute kidney injury and intestinal mucosal injury in an ischemia-reperfusion mouse model.19, 20 Further studies are needed to investigate whether and how changes in SCFA-producing microbiota truly translate into changes in plasma levels of SCFAs.

Because gut microbiota plays a role in systemic inflammation, metabolic syndrome, vascular dysfunction and atherosclerosis, modulating gut microbiota and its metabolites is a possible therapeutic strategy. Prebiotics are nondigestible ingredients that selectively alter the growth or activity of certain species of the intestinal microbiota. The reduction of p-cresyl sulfate and indoxyl sulfate was observed in hemodialysis patients receiving inulin.21 Probiotics, organisms in food and dietary supplements that can confer health benefits on the host, reduced uremic toxins in the gut through several mechanisms including enhancement of epithelial barrier function, the production and secretion of mucin, inhibition of pathogenic bacteria adhesion, regulation of epithelial homeostasis, and increased cell survival.22 The administration of a probiotic bacterial formulation in CKD patients was associated with a significant decrease in blood urea nitrogen levels and significant improvement in the quality of life and serum creatinine and uric levels.23 Targeting healthy reactive oxygen production in the gut with probiotics was beneficial for the prevention of CKD progression.23 Meanwhile, direct removal of gut-derived toxins has also been a focus in the treatment of patients with CKD.4 However, we have yet to see concrete evidence on the benefits of gut dysbiosis manipulation or interventions targeting gut microbiota in patients with cardiovascular or cardiorenal syndrome.

In summary, multiple factors link the gut and cardiorenal pathophysiology. In particular, the metabolic potential of gut microbiota has gained much attention as a contributing factor in the development of CVD and CKD. Gut microbiota and cardiorenal syndrome can potentiate each other, leading to a vicious cycle. Further understanding of these gut-cardiorenal interactions may result in novel diagnostic and therapeutic approaches as well as improve the long-term clinical care of these patients. This exciting new area of gut-cardiorenal interaction needs further investigation, and long-term intervention studies are warranted to clarify potential benefits of such strategies in modulating gut microbiota.

FUNDING

W. Tang is supported by grants from the National Institutes of Health (NIH) and the Office of Dietary Supplements (P20HL113452, R01DK106000, R01HL126827) related to the content of this article.

CONFLICTS OF INTEREST

None declared.

.

Corresponding author: Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid Avenue, Desk J3-4, Cleveland, Ohio 44195, United States. tangw@ccf.org

Bibliography

1. Duranton F, Cohen G, De Smet R, et al. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol. 2012;23:1258-70.
2. Yu M, Kim YJ, Kang DH. Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clin J Am Soc Nephrol. 2011;6:30-9.
3. Vaziri ND, Goshtasbi N, Yuan J, et al. Uremic plasma impairs barrier function and depletes the tight junction protein constituents of intestinal epithelium. Am J Nephrol. 2012;36:438-43.
4. Ramezani A, Raj DS. The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol. 2014;25:657-70.
5. Winslow MM, Gallo EM, Neilson JR, Crabtree GR. The calcineurin phosphatase complex modulates immunogenic B cell responses. Immunity. 2006;24:141-52.
6. Dinakaran V, Rathinavel A, Pushpanathan M, Sivakumar R, Gunasekaran P, Rajendhran J. Elevated levels of circulating DNA in cardiovascular disease patients: metagenomic profiling of microbiome in the circulation. PLoS One. 2014;9:e105221.
7. Shi K, Wang F, Jiang H, et al. Gut bacterial translocation may aggravate microinflammation in hemodialysis patients. Dig Dis Sci. 2014;59:2109-17.
8. Wang F, Jiang H, Shi K, Ren Y, Zhang P, Cheng S. Gut bacterial translocation is associated with microinflammation in end-stage renal disease patients. Nephrology (Carlton). 2012;17:733-8.
9. Pasini E, Aquilani R, Testa C, et al. Pathogenic Gut Flora in Patients With Chronic Heart Failure. JACC Heart Fail. 2016;4:220-7.
10. Tang WH, Wang Z, Fan Y, et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. J Am Coll Cardiol. 2014;64:1908-14.
11. Tang WH, Wang Z, Kennedy DJ, et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res. 2015;116:448-55.
12. Backhed F. Meat-metabolizing bacteria in atherosclerosis. Nat Med. 2013;19:533-4.
13. Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19:576-85.
14. Wang Z, Roberts AB, Buffa JA, et al. Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis. Cell. 2015;163:1585-95.
15. Durgan DJ, Ganesh BP, Cope JL, et al. Role of the Gut Microbiome in Obstructive Sleep Apnea-Induced Hypertension. Hypertension. 2016;67:469-74.
16. Pluznick J. A novel SCFA receptor, the microbiota, and blood pressure regulation. Gut Microbes. 2014;5:202-7.
17. Weisz OA, Gibson GA, Leung SM, Roder J, Jeromin A. Overexpression of frequenin, a modulator of phosphatidylinositol 4-kinase, inhibits biosynthetic delivery of an apical protein in polarized madin-darby canine kidney cells. J Biol Chem. 2000;275:24341-7.
18. Holmes E, Loo RL, Stamler J, et al. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature. 2008;453:396-400.
19. Aguilar-Nascimento JE, Salomao AB, Nochi RJ, Nascimento M, Neves Jde S. Intraluminal injection of short chain fatty acids diminishes intestinal mucosa injury in experimental ischemia-reperfusion. Acta Cir Bras. 2006;21:21-5.
20. Andrade-Oliveira V, Amano MT, Correa-Costa M, et al, Gut Bacteria Products Prevent AKI. Induced by Ischemia-Reperfusion. J Am Soc Nephrol. 2015;26:1877-88.
21. Meijers BK, De Preter V, Verbeke K, Vanrenterghem Y, Evenepoel P. p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrol Dial Transplant. 2010;25:219-24.
22. Neish AS. Redox signaling mediated by the gut microbiota. Free Radic Res. 2013;47:950-7.
23. Vitetta L, Linnane AW, Gobe GC. From the gastrointestinal tract (GIT) to the kidneys: live bacterial cultures (probiotics) mediating reductions of uremic toxin levels via free radical signaling. Toxins (Basel). 2013;5:2042-57.

1885-5857/© 2017 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved

Cookies
x
To improve our services and products, we use cookies (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.
Cookies policy
x
To improve our services and products, we use cookies (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.